Results of treating bleeding disorders with Mongolian medicine Gurgem-8
- VernacularTitle:Цус зогсоох Гүргэм-8 Монгол эмээр цус нэвчрэх өвчнийг эмчилсэн дүн
- Author:
Gou Qing
1
;
Khaliun B
2
;
Chen Shana
3
;
Tsend-Ayush D
4
Author Information
1. International School of Mongolian Medicine (ISMM), MNUMS
2. Department of Internal Medicine, ISMM
3. International Mongolian Hospital of Inner Mongolia
4. ISMM, MNUMS, IMTM
- Publication Type:Journal Article
- Keywords:
Immune thrombocytopenia;
Traditional drug;
Immune cell;
CD4/CD8
- From:
Mongolian Journal of Health Sciences
2025;85(1):201-206
- CountryMongolia
- Language:Mongolian
-
Abstract:
Background:From the perspective of Mongolian medicine, hemorrhagic disease is a symptom of bleeding from any part
of the body. This disease was compared to the immune thrombocytopenia disease of modern medicine. The treatment of
this disease using two medical methods and the prevention of complications and relapses are issues facing the healthcare
sector. In this regard, we have chosen this topic to clarify and prove the mechanism of action of the Mongolian drug Gurgem-8, which is widely used to treat bleeding disorders.
Aim: To evaluate the therapeutic efficacy of Gurgem-8, in haemostatic treatment.
Materials and Methods: The study was conducted using a randomized, controlled (active), open label, single centered
clinical trial method. The study was conducted in two phases. First, an acute toxicity study of the Gurgem-8, was conducted in accordance with OECD guideline 423 and evaluated according to GHS classification. A chronic toxicity study
was also conducted on Wistar rats (n=20) given the Gurgem-8, at doses of 500 mg/kg, 100 mg/kg, and 150 mg/kg daily
for 60 days. Second, a clinical study was conducted on a total of 74 patients, who were randomly divided into 2 groups.
The treatment group was given 3 grams of the Gurgem-8, daily, and the comparison group was given 4 capsules of Sheng
Xue Xiao Ban Jiao Nang 3 times a day. The results were determined by laboratory methods. The study was conducted
with the approval of the Research Ethics Committee of Mongolian National University od Medical Sciences (2024.01.19
№2024/3-01).
Results: In the acute toxicity study, Turmeric-8 was found to be of low toxicity according to the GHS classification. No
mortality was observed in the chronic toxicity test. As a result of the clinical study, there were significant differences in the
blood hemoglobin (χ2=73.923, P<0.001), platelet (χ2=62.465, P<0.001), erythrocyte (χ2=77.113, P<0.001) and leukocyte
(χ2=14.771, P<0.001) cell counts between the Gurgem-8, drug group and the comparison group. It was also determined
that the platelet (χ2=138.3, P<0.001), erythrocyte (χ2=85.405, P<0.001) and leukocyte (χ2=10.961, P=0.027) cell counts
were directly related to the treatment period and the group. When determining the effect on immune cells, there was no
significant difference in the lymphocyte cell content before and after treatment (CD4+: t=0.233, P=0.817; CD8+: t=-0.264, P=0.793; CD4/CD8:Z=-0.119, P=0.905). However, the CD4/CD8 ratio was statistically significantly increased in
each of the Gurgem-8, drug group and the comparison group (P<0.001, P=0.001).
Conclusion:In immune thrombocytopenia diseases, the Gurgem-8, has the effect of reducing hemoglobin levels in the
blood, increasing platelet counts, reducing CD4+ and CD8+ T cell counts, and increasing the CD4/CD8 ratio.
- Full text:202505271635318246201-206.pdf
